Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s stock price was up 7.4% during mid-day trading on Tuesday . The company traded as high as $20.00 and last traded at $19.53. Approximately 178,578 shares traded hands during trading, a decline of 77% from the average daily volume of 780,994 shares. The stock had previously closed at $18.18.
Wall Street Analysts Forecast Growth
MTSR has been the topic of several research analyst reports. Evercore ISI started coverage on shares of Metsera in a report on Tuesday, February 25th. They set an "outperform" rating on the stock. Bank of America initiated coverage on Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $38.00 price target for the company. Guggenheim began coverage on Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price target for the company. Finally, Cantor Fitzgerald started coverage on Metsera in a report on Tuesday, February 25th. They issued an "overweight" rating on the stock.
Get Our Latest Stock Analysis on MTSR
Metsera Price Performance
The company's fifty day moving average price is $24.82.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
